Devyser
Manufacturing · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Instrumentvägen 19, Hägersten, Stockholm...Phone Number
+46 856215850Website
www.devyser.comRevenue
$17.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Devyser
Devyser is a pioneering provider of diagnostic DNA test kits designed for laboratories worldwide, offering fast, precise, and easy-to-use genetic testing solutions. Their product range includes tests for various diagnostic areas such as oncology, hematology, reproductive health, and cystic fibrosis, among others. The company aims to enhance personalized healthcare by enabling accurate and rapid diagnoses, thereby improving patient outcomes. Devyser's clients primarily include laboratories and healthcare providers seeking advanced genetic testing capabilities.Explore more
Devyser Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Devyser your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Devyser
Devyser, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Devyser has new funding data
Product Launch: Get notified when Devyser launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Devyser recently announced quarterly report
Check out if Devyser is spiking on competitors!
Click to see if Devyser had a recent Job posting/layoffs
Check if Devyser has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Devyser
Find 3 more new buyers
Company Profile Activity
Activity Insights
Devyser is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Devyser is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Devyser.
Devyser financials insights
Gather financial insights about Devyser, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Grant
$900K
Devyser Tech Stack
A closer look at the technologies used by Devyser
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Seeking Replacement
Person-Based
Person-Based
Person-Based
Devyser News & Media
Devyser announces that Chief Commercial Officer will leave the company - TradingView
Devyser Diagnostics AB today announces that the company’s Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.“During Theis’ time at the company, Devyser has built a strong and well‑functioning sales organization with solid foundati…Devyser Diagnostics AB (publ) (DVYSF) Q4 2025 Earnings Call Transcript
Devyser Diagnostics AB (publ) (DVYSF) Q4 2025 Earnings Call February 12, 2026 3:00 AM ESTCompany ParticipantsJan Wahlstrom - Chief Executive OfficerSabina...Devyser wins tender for non-invasive fetal RHD testing in Wales
Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in maternal plasma during pregnancy. The tender with Wales Blood Services covers fetal RHD testing in Wales and is valid for a period of three years, with the potential of a two-year extension. Indicative order value is estimated to amount to 1 million SEK annually. “This is a strategic breakthrough in the UK market, and I am very proudDevyser Diagnostics AB publishes quarterly report for July to September 2023
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further improvement in EBIT and continued high gross margins. Devyser’s transplant products were given IVDR approvals during the quarter and Thermo Fisher Scientific, our commercial partner in the transplant field, began the launching of the transplant products in North America and Europe.” Fredrik Alpsten, CEO, Devyser The quarter from July to September 2023 · Net sales amounted to SEK 46.7 million
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Devyser
Sign Up For FreeTo access detailed company insights
Devyser is a pioneering provider of diagnostic DNA test kits designed for laboratories worldwide, offering fast, precise, and easy-to-use genetic testing solutions. Their product range includes tests for various diagnostic areas such as oncology, hematology, reproductive health, and cystic fibrosis, among others. The company aims to enhance persona... Read More
